Literature DB >> 11309340

Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

H Takayasu1, H Horie, E Hiyama, T Matsunaga, Y Hayashi, Y Watanabe, S Suita, M Kaneko, F Sasaki, K Hashizume, T Ozaki, K Furuuchi, M Tada, N Ohnuma, A Nakagawara.   

Abstract

Hepatoblastoma (HBL) is the most common malignant liver tumor in young children. Recent reports have shown that the beta-catenin gene was frequently mutated or deleted in HBLS: To elucidate the role of beta-catenin abnormalities in HBLs, we searched for mutations of beta-catenin and APC as well as expression of the target genes, cyclin D1, c-myc, and fibronectin, in 68 primary HBLS: The mutation analysis revealed that 44 (65%) tumors carried missense mutations or deletions of beta-catenin, all of which were somatic and targeted to the exon 3 encoding the amino acid residues involved in its degradation. However, no loss of function mutation of the APC gene was detected by the yeast functional assay. Of interest, beta-catenin mutation was significantly correlated with overexpression of the target genes, cyclin D1 and fibronectin, but not with that of c-myc in HBLs as measured by quantitative real-time reverse transcription-PCR. The immunohistochemical studies in 15 HBLs demonstrated that the nuclear/cytoplasmic accumulation of beta-catenin was positive in 13 tumors, 9 of which had the deletion or mutation of the gene. The significant correlation between the beta-catenin gene abnormality and the positive staining of cyclin D1 was also confirmed. Furthermore, the nuclear accumulation of beta-catenin was strongly associated with the poorly differentiated tumor cell components as well as with the positive staining of cyclin D1 within the tumor. Thus, our present results suggested that the gain of function mutation of beta-catenin played a crucial role in the malignant progression of HBL in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309340

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

1.  Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets.

Authors:  Masahiro Sekiguchi; Masafumi Seki; Tomoko Kawai; Kenichi Yoshida; Misa Yoshida; Tomoya Isobe; Noriko Hoshino; Ryota Shirai; Mio Tanaka; Ryota Souzaki; Kentaro Watanabe; Yuki Arakawa; Yasuhito Nannya; Hiromichi Suzuki; Yoichi Fujii; Keisuke Kataoka; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Teppei Shimamura; Yusuke Sato; Aiko Sato-Otsubo; Shunsuke Kimura; Yasuo Kubota; Mitsuteru Hiwatari; Katsuyoshi Koh; Yasuhide Hayashi; Yutaka Kanamori; Mureo Kasahara; Kenichi Kohashi; Motohiro Kato; Takako Yoshioka; Kimikazu Matsumoto; Akira Oka; Tomoaki Taguchi; Masashi Sanada; Yukichi Tanaka; Satoru Miyano; Kenichiro Hata; Seishi Ogawa; Junko Takita
Journal:  NPJ Precis Oncol       Date:  2020-07-07

2.  Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.

Authors:  Sarah A Comerford; Elizabeth A Hinnant; Yidong Chen; Hima Bansal; Shawn Klapproth; Dinesh Rakheja; Milton J Finegold; Dolores Lopez-Terrada; Kathryn A O'Donnell; Gail E Tomlinson; Robert E Hammer
Journal:  JCI Insight       Date:  2016-10-06

3.  Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases.

Authors:  William B Laskin; Jerzy P Lasota; John F Fetsch; Anna Felisiak-Golabek; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

4.  Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.

Authors:  Débora Sinner; Jennifer J Kordich; Jason R Spence; Robert Opoka; Scott Rankin; Suh-Chin J Lin; Diva Jonatan; Aaron M Zorn; James M Wells
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 5.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

6.  Downregulation of sFRP-2 by epigenetic silencing activates the β-catenin/Wnt signaling pathway in esophageal basaloid squamous cell carcinoma.

Authors:  Tsuyoshi Saito; Hiroyuki Mitomi; Abdukadir Imamhasan; Takuo Hayashi; Keiko Mitani; Michiko Takahashi; Yoshiaki Kajiyama; Takashi Yao
Journal:  Virchows Arch       Date:  2014-01-26       Impact factor: 4.064

7.  Genomic Profiling Reveals Unique Molecular Alterations in Hepatoblastomas and Adjacent Hepatocellular Carcinomas in B6C3F1 Mice.

Authors:  Sachin Bhusari; Arun R Pandiri; Hiroaki Nagai; Yu Wang; Julie Foley; Hue-Hua L Hong; Thai-Vu Ton; Michael DeVito; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; David E Malarkey; Michelle J Hooth; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-08-18       Impact factor: 1.902

8.  Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer.

Authors:  Sandra Waalkes; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Gesa Vetter; Jan U Becker; Arnulf Stenzl; Axel S Merseburger; Andres J Schrader; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

9.  Genome-wide analysis of DNA methylation in hepatoblastoma tissues.

Authors:  Ximao Cui; Baihui Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

10.  Fibronectin 1 protein expression in clear cell renal cell carcinoma.

Authors:  S Steffens; A J Schrader; Gesa Vetter; H Eggers; H Blasig; J Becker; M A Kuczyk; J Serth
Journal:  Oncol Lett       Date:  2012-01-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.